Company / PP&E (Net)
GT Biopharma, Inc. PP&E (Net) History
FY2014-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$6.0K
FY2017
5-year range
$5.0K / $6.0K
FY2014-FY2017
Trend
+20.0%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$6,000 in FY2017 with a 3-year CAGR of +0.0%.
Remained stable around $6,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +0.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +0.0%, indicating consistent growth.
- In FY2017, pp&e (net) increased 20.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2020 | - | - |
| FY2017 | $6.0K | +20.0% |
| FY2016 | $5.0K | -16.7% |
| FY2015 | $6.0K | +0.0% |
| FY2014 | $6.0K | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2017 · SEC 10-K · Updated Jun 24, 2026